NO20003261L - Mixtures derived from Mycobacterium vaccae and methods for their use - Google Patents

Mixtures derived from Mycobacterium vaccae and methods for their use

Info

Publication number
NO20003261L
NO20003261L NO20003261A NO20003261A NO20003261L NO 20003261 L NO20003261 L NO 20003261L NO 20003261 A NO20003261 A NO 20003261A NO 20003261 A NO20003261 A NO 20003261A NO 20003261 L NO20003261 L NO 20003261L
Authority
NO
Norway
Prior art keywords
vaccae
methods
delipidated
mycobacterium vaccae
mixtures derived
Prior art date
Application number
NO20003261A
Other languages
Norwegian (no)
Other versions
NO20003261D0 (en
Inventor
Paul Tan
James Watson
Elizabeth S Visser
Margot A Skinner
Ross L Prestidge
Original Assignee
Genesis Research & Dev Corp Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/997,362 external-priority patent/US5985287A/en
Priority claimed from US08/997,080 external-priority patent/US5968524A/en
Priority claimed from US09/095,855 external-priority patent/US6160093A/en
Priority claimed from US09/205,426 external-priority patent/US6406704B1/en
Application filed by Genesis Research & Dev Corp Lt filed Critical Genesis Research & Dev Corp Lt
Publication of NO20003261D0 publication Critical patent/NO20003261D0/en
Publication of NO20003261L publication Critical patent/NO20003261L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Det beskrives blandinger som forekommer i, eller kan avledes fra, Mycobactehum vaccae, samt fremgangsmåter for deres anvendelse ved behandling, forebyggelse og påvisning av forstyrrelser inklusivt infeksjonssykdommer, immunforstyrrelser og cancer. Fremgangsmåter for forbedring av immunresponsen mot et antigen og som innbefatter administrering av M. vaccae-kulturfiltrat, delipiderte M. vaccae-celler, delipiderte og deglykolipiderte M. vaccae-celler utarmet med hensyn til mykolsyrer, og delipiderte og deglykolipiderte M. vaccae-celler utarmet med hensyn til mykolsyrer og arabinogalaktan, er også beskrevet.It describes compounds that occur in, or can be derived from, Mycobactehum vaccae, as well as methods for their use in the treatment, prevention and detection of disorders including infectious diseases, immune disorders and cancer. Methods of enhancing the immune response to an antigen comprising administering M. vaccae culture filtrate, delipidated M. vaccae cells, delipidated and deglycolipidated M. vaccae cells depleted of mycolic acids, and delipidated and deglycolipidated M. vaccae cells depleted with respect to mycolic acids and arabinogalactan, is also described.

NO20003261A 1997-12-23 2000-06-22 Mixtures derived from Mycobacterium vaccae and methods for their use NO20003261L (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99662497A 1997-12-23 1997-12-23
US08/997,362 US5985287A (en) 1996-08-29 1997-12-23 Compounds and methods for treatment and diagnosis of mycobacterial infections
US08/997,080 US5968524A (en) 1997-12-23 1997-12-23 Methods and compounds for the treatment of immunologically-mediated psoriasis
US09/095,855 US6160093A (en) 1996-08-29 1998-06-11 Compounds and methods for treatment and diagnosis of mycobacterial infections
US15618198A 1998-09-17 1998-09-17
US09/205,426 US6406704B1 (en) 1996-08-29 1998-12-04 Compounds and methods for treatment and diagnosis of mycobacterial infections
PCT/NZ1998/000189 WO1999032634A2 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use

Publications (2)

Publication Number Publication Date
NO20003261D0 NO20003261D0 (en) 2000-06-22
NO20003261L true NO20003261L (en) 2000-08-22

Family

ID=27557521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003261A NO20003261L (en) 1997-12-23 2000-06-22 Mixtures derived from Mycobacterium vaccae and methods for their use

Country Status (15)

Country Link
EP (1) EP1044273A2 (en)
JP (1) JP2002514385A (en)
CN (1) CN1294632A (en)
AU (1) AU746311B2 (en)
BR (1) BR9814432A (en)
CA (1) CA2315539A1 (en)
HU (1) HUP0100352A2 (en)
ID (1) ID26327A (en)
IL (1) IL136821A0 (en)
MX (1) MXPA00006168A (en)
NO (1) NO20003261L (en)
NZ (1) NZ505834A (en)
PL (1) PL341697A1 (en)
TR (1) TR200001948T2 (en)
WO (1) WO1999032634A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
JP4415200B2 (en) * 1999-01-29 2010-02-17 大塚製薬株式会社 Late-growing mycobacterial polypeptide
GB9903539D0 (en) * 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US6462669B1 (en) 1999-04-06 2002-10-08 E. P . Survivors Llc Replaceable LED modules
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
CA2383496A1 (en) * 1999-07-12 2001-01-18 Genesis Research & Development Corporation Limited Compounds for treatment of infectious and immune system disorders and methods for their use
CA2381139A1 (en) * 1999-08-31 2001-03-08 Michael Niederweis Method for the production of a channel forming protein
NZ517409A (en) * 1999-08-31 2004-05-28 Novozymes As RP-II properties with amino acid substitutions used in detergent compositions and additives
US7217554B2 (en) 1999-08-31 2007-05-15 Novozymes A/S Proteases and variants thereof
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
EP1254953A4 (en) * 1999-12-28 2004-06-02 Toyoshima Kumao MATURING AGENT FOR IMMATURE DENDRITIC CELLS
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
WO2002094184A2 (en) * 2001-05-11 2002-11-28 Corixa Corporation Vaccines for the treatment of autoimmune disease
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
GB0303507D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
RU2695462C2 (en) * 2014-01-09 2019-07-23 Трансген Са Hybridisation of heterooligomer mycobacterial antigens
CN113527440B (en) * 2021-08-10 2022-12-23 昆明医科大学 A kind of polypeptide with the functions of improving immunity, anti-tumor and prolonging life and its application
CN119162167B (en) * 2024-11-21 2025-03-11 四川大学华西医院 Extraction method of mycobacteria genome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Also Published As

Publication number Publication date
AU1893699A (en) 1999-07-12
AU746311B2 (en) 2002-04-18
JP2002514385A (en) 2002-05-21
MXPA00006168A (en) 2005-02-24
CN1294632A (en) 2001-05-09
EP1044273A2 (en) 2000-10-18
TR200001948T2 (en) 2001-02-21
WO1999032634A3 (en) 1999-12-02
PL341697A1 (en) 2001-04-23
WO1999032634A2 (en) 1999-07-01
IL136821A0 (en) 2001-06-14
ID26327A (en) 2000-12-14
BR9814432A (en) 2000-10-10
NZ505834A (en) 2002-12-20
HUP0100352A2 (en) 2001-06-28
CA2315539A1 (en) 1999-07-01
NO20003261D0 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
NO20003261L (en) Mixtures derived from Mycobacterium vaccae and methods for their use
NO986173L (en) Procedure for activating dendritic cells
ATE326479T1 (en) VARIANTS OF HUMAN PAPILLOMA VIRUS ANTIGENS
ATE314095T1 (en) VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
IL192679A0 (en) Aglyco products and uses thereof
NO20064388L (en) Casein-derived peptides and therapeutic uses thereof
ATE271063T1 (en) PURINE-L-NUCLEOSIDES, THEIR ANALOGUES AND USES
DK0528859T3 (en) Oral vaccine which includes antigen attached to the surface of red blood cells
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
CA2033640A1 (en) Vaccines against cancer and infectious diseases
PT1526172E (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
NL930133I2 (en) Vaccine against hepatitis B virus, method and transformed eukaryotic cells and the preparation of that vaccine.
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
DE68915165D1 (en) IMMUNOGENIC SECTIONS OF HUMAN PARAIN INFLUENCE VIRUS TYPE 3 CONTAINING CHIMERIC GLYCOPROTEINS.
NO920331D0 (en) BIOLOGICAL PREPARATION AND USE THEREOF
NO892125D0 (en) COMBINATION OF ANGIOTENSIN-CONVERSIBLE ENZYME INHIBITORS WITH POTASSIUM CHANNEL MODULATORS AND THEIR USE IN PHARMACEUTICALS.
EP1028754A4 (en) PREVENTION OF IMMUNE REACTIVITY DUE TO DEPTH OR INHIBITION OF ANTIGENT PRESENTING CELLS
WO1999049876A3 (en) Bacterial or yeast extracts which stimulate the production of defensins and methods of use thereof
DE69734461D1 (en) USE OF MYCOBACTERIUM VACCAE FOR THE THERAPY OF CHRONIC TIRED SYNDROME
NO922422L (en) MATERIAL WITH ADHERENT BONDED CELLS, AND PROCEDURES FOR PRODUCING VIRUS / VIRUS ANTIGENS
DK0551275T3 (en) Non-A non-B sequences
Hanley et al. Clinical use of CMV-specific T cells derived from CMV-naïve donors
JPS52117489A (en) L-asparaginase-embedded fibrin and heat stabilization thereof
DE3880625D1 (en) USE OF THE TUMOR NECROSE FACTOR AS ADJUVANS THE IMMUNE RESPONSE.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application